Peptide Research 2026: Market Surge to $68B Driven by GLP-1s, AI Discovery, and Novel Therapeutics
Title: Peptide Research 2026: Market Surge to $68B Driven by GLP-1s, AI Discovery, and Novel Therapeutics Abstract: The global peptide market is projected to reach $68 billion by 2026, fueled by GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) and AI-driven discovery platforms. Key trends include a shift toward high-purity (>98%) synthetic peptides for metabolic and oncology indications. Leading brands (Novo Nordisk, Eli Lilly) dominate via clinical efficacy, while emerging Chinese manufacturers offer cost advantages but require rigorous GMP certification (e.g., cGMP, ISO 9001). Technical trade-offs: solid-phase synthesis ensures scalability but limits long-chain peptides; liquid-phase excels for complex structures. Logistics demand cold-chain (-20°C) and lyophilized formats to maintain stability. Selection criteria prioritize purity, endotoxin levels (<1 EU/mg), and third-party HPLC/MS validation. Industry challenges include counterfeit risks and regulatory divergence (FDA vs. NMPA).